Table 1.
Key Pharmacokinetic Characteristics of Rapid-Acting Insulin Analogs19
| Afrezzaa (Insulin Human) | Novologb (Insulin Aspart) | Humalogc (Insulin Lispro) | Apidrad (Insulin Glulisine) | |
|---|---|---|---|---|
| Route of administration | Inhaled | Subcutaneous | ||
| Onset of action (hours) | ∼1 | 1 to 3 | 0.25 to 0.50 | 1.6 to 2.8 |
| Duration of action (hours) | 2.5 to 3.0 | 3 to 5 | ∼5 | 3 to 4 |
| Half-life (minutes) | 28 to 39 | 81 | ∼60 | 42 |
| Tmax (minutes) | 12 to 15 | 40 to 50 | 30 to 90 | 36 to 120 |
a
MannKind Corp./Sanofi-Aventis US
b
Novo Nordisk
c
Eli Lilly
d
Sanofi-Aventis US
Tmax = time to peak plasma concentration